Brief: Boehringer Ingelheim, Ose Immunotherapeutics Present Phase 1 Results With Sirpα Inhibitor Bi 765063 In Advanced Solid Tumors At ESMO

Ose Immunotherapeutics SA

16/09/2021 17:24

Sept 16 (Reuters) - Ose Immunotherapeutics SA  OSE.PA :
    * BOEHRINGER INGELHEIM AND OSE IMMUNOTHERAPEUTICS PRESENT
PHASE 1
RESULTS WITH FIRST-IN-CLASS SIRPΑ INHIBITOR BI 765063 IN
ADVANCED SOLID TUMORS AT ESMO 2021
    * OSE IMMUNOTHERAPEUTICS SA - DATA FROM PHASE 1 DOSE
ESCALATION
INDICATE BI 765063 MONOTHERAPY OR IN COMBINATION WITH
EZABENLIMAB IS WELL TOLERATED
    * OSE IMMUNOTHERAPEUTICS SA - DATA INDICATES IT SHOWS
PROMISING
ACTIVITY IN HEAVILY PRE-TREATED SOLID TUMOR PATIENTS

Source text for Eikon:  ID:nGNX1jHccZ 
Further company coverage:  OSE.PA 

 ((Reuters.Briefs@thomsonreuters.com;))